Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will release its first quarter 2021 financial results on May 6, 2021, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company focuses on developing vaccines, with its first product, HEPLISAV-B®, already approved in the U.S. and EU for hepatitis B prevention in adults. Dynavax continues to advance its CpG 1018 adjuvant through collaborations for COVID-19, pertussis, and universal influenza vaccines.

Positive

• Approval of HEPLISAV-B® for hepatitis B prevention in the U.S. and EU.
• Advancement of CpG 1018 adjuvant in multiple vaccine collaborations.

Negative

• None.

EMERYVILLE, Calif., April 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2021 financial results on Thursday, May 6, 2021, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 4533398.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2021-financial-results-and-host-conference-call-on-may-6-2021-301275359.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its Q1 2021 financial results?

Dynavax will report its Q1 2021 financial results on May 6, 2021.

What products does Dynavax Technologies have?

Dynavax has developed HEPLISAV-B®, a vaccine for hepatitis B, and is advancing CpG 1018 adjuvant for various vaccines.

What time is the Dynavax conference call on May 6, 2021?

The conference call will start at 4:30 p.m. ET.

How can I access the conference call for Dynavax?

The conference call can be accessed via the 'Events & Presentations' page on Dynavax's investor website or by dialing (866) 420-4066 for domestic and (409) 217-8237 for international.

What is Dynavax's stock symbol?

Dynavax's stock symbol is DVAX.